SNPMiner Trials (Home Page)
Report for Mutation D565H
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.
Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily.
NCT03067415 Glaucoma, Primary Open Angle Ocular Hypertension Drug: D565H(Latanoprost 25㎍/㎖) Drug: D565(Latanoprost 50㎍/㎖) MeSH:Glaucoma Ocular Hypertension Glaucoma, Open-Angle Hypertension
HPO:Glaucoma Hypertension
A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.. Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily. --- D565H ---
A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.. Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily. --- D565H --- --- D565H ---
A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.. Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily. --- D565H --- --- D565H --- --- D565H ---
Impossible subjects who participate in clinical trial by investigator's decision Glaucoma, Primary Open Angle Ocular Hypertension Glaucoma Ocular Hypertension Glaucoma, Open-Angle Hypertension A Multi center, Randomized, Double-blind, Parallel design, Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once daily in primary open angle glaucoma or ocular hypertension patients. --- D565H ---
Primary Outcomes
Description: Mean baseline intraocular pressure change Mean intraocular pressure change after 4 weeks
Measure: Change in mean intraocular pressure at 4 weeks compared to baseline Time: Baseline, 4 weeksSecondary Outcomes
Description: Mean baseline intraocular pressure change Mean intraocular pressure change after 2 weeks
Measure: Change in mean intraocular pressure at 2 weeks compared to baseline Time: Baseline, 2 weeksDescription: IOP variation by measurement time
Measure: Changes in intraocular pressure by measurement time Time: 2 weeks, 4 weeksOther Outcomes
Description: Adverse events, history, medications, signs of vitality, physical examination, etc.
Measure: Safety assessed by the incidence of adverse event, History, Medication Time: up to 4 weeks